Jeet Mukherjee
Stock Analyst at BTIG
(3.65)
# 789
Out of 5,141 analysts
28
Total ratings
50%
Success rate
10.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Reiterates: Buy | $26 | $12.32 | +111.04% | 2 | Feb 10, 2026 | |
| KYMR Kymera Therapeutics | Reiterates: Buy | $138 | $87.40 | +57.89% | 5 | Feb 3, 2026 | |
| MNPR Monopar Therapeutics | Reiterates: Buy | $104 | $55.41 | +87.69% | 5 | Feb 2, 2026 | |
| NRIX Nurix Therapeutics | Reiterates: Buy | $30 | $15.78 | +90.11% | 5 | Jan 29, 2026 | |
| PVLA Palvella Therapeutics | Reiterates: Buy | $192 | $85.66 | +124.14% | 4 | Jan 29, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Buy | $14 | $5.65 | +147.79% | 3 | Jan 13, 2026 | |
| BCAX Bicara Therapeutics | Initiates: Buy | $28 | $15.48 | +80.88% | 1 | Jan 8, 2026 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $11 | $5.73 | +91.97% | 1 | Dec 18, 2025 | |
| ARVN Arvinas | Maintains: Buy | $10 → $14 | $11.99 | +16.76% | 2 | Oct 30, 2025 |
Aardvark Therapeutics
Feb 10, 2026
Reiterates: Buy
Price Target: $26
Current: $12.32
Upside: +111.04%
Kymera Therapeutics
Feb 3, 2026
Reiterates: Buy
Price Target: $138
Current: $87.40
Upside: +57.89%
Monopar Therapeutics
Feb 2, 2026
Reiterates: Buy
Price Target: $104
Current: $55.41
Upside: +87.69%
Nurix Therapeutics
Jan 29, 2026
Reiterates: Buy
Price Target: $30
Current: $15.78
Upside: +90.11%
Palvella Therapeutics
Jan 29, 2026
Reiterates: Buy
Price Target: $192
Current: $85.66
Upside: +124.14%
Perspective Therapeutics
Jan 13, 2026
Reiterates: Buy
Price Target: $14
Current: $5.65
Upside: +147.79%
Bicara Therapeutics
Jan 8, 2026
Initiates: Buy
Price Target: $28
Current: $15.48
Upside: +80.88%
Foghorn Therapeutics
Dec 18, 2025
Initiates: Buy
Price Target: $11
Current: $5.73
Upside: +91.97%
Arvinas
Oct 30, 2025
Maintains: Buy
Price Target: $10 → $14
Current: $11.99
Upside: +16.76%